{"nctId":"NCT04918771","briefTitle":"Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old","startDateStruct":{"date":"2021-04-29","type":"ACTUAL"},"conditions":["Acute Respiratory Viral Infection"],"count":435,"armGroups":[{"label":"Raphamin","type":"EXPERIMENTAL","interventionNames":["Drug: Raphamin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Raphamin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients of either gender aged 12 to 18 years.\n2. Diagnosis of ARVI based on medical examination: axillary temperature ≥ 37.8°C at examination + non-specific flu-like symptoms score ≥4, nasal/throat/chest symptom score ≥2.\n3. The first 24 hours after ARVI onset.\n4. Contraceptive measures by sexually active adolescents of both genders during the study.\n5. Patient information sheet (informed consent form) signed by one parent/adoptive parent of the patient and there is also a signed patient information sheet (informed consent form) for children aged 14 and over.\n\nExclusion Criteria:\n\n1. Clinical symptoms of severe influenza/ARVI requiring hospitalization.\n2. Positive SARS-CoV-2 (COVID-19/Coronavirusdisease2019) antigen test.\n3. Suspected pneumonia, bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) requiring administration of antibiotics from the first day of illness.\n4. Suspected initial manifestations of diseases with symptoms similar to ARVI at onset (other infectious diseases, flu-like syndrome at the onset of systemic connective tissue diseases, and other pathology).\n5. Patients requiring antiviral medication prohibited within the study.\n6. Medical history of primary and secondary immunodeficiency.\n7. Medical history/suspicion of oncology of any localization (except for benign neoplasms).\n8. Aggravation or decompensation of chronic diseases (diabetes mellitus, infantile cerebral paralysis, cystic fibrosis, primary ciliary dyskinesia, bronchopulmonary dysplasia, respiratory and ENT congenital defects, etc.) affecting a patient's ability to participate in the clinical trial.\n9. Malabsorption syndrome, including congenital or acquired lactase or other disaccharidase deficiency, galactosemia.\n10. Allergy/ hypersensitivity to any component of the study drugs used in the treatment.\n11. Pregnancy. Breast-feeding.\n12. Use of medications specified in the section \"Prohibited Concomitant Therapy\" within two weeks prior to inclusion in the study.\n13. Patients whose parents/adopters, from the investigator's point of view, will not comply with the observation requirements during the study or follow the procedure for taking the study drugs.\n14. Medical history of mental diseases of the patient or their parent(s)/adoptive parents.\n15. Participation in other clinical trials for 3 months prior to enrollment in this study.\n16. Patient's parents/adopters who are related to any of the on-site research personnel directly involved in the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).\n17. The patient's parent/adopter who work for OOO \"NPF \"MATERIA MEDICA HOLDING\" (i.e. the company's employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"18 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Resolution of Acute Respiratory Viral Infection (ARVI) Symptoms (ARVI, Confirmed by Polymerase Chain Reaction (PCR)).","description":"Outcome Measure is evaluated on the basis of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from \"0\" to \"42\". The TSS higher score is the worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.7"},{"groupId":"OG001","value":"4.4","spread":"2.6"}]}]}]},{"type":"SECONDARY","title":"Severity of ARVI (Clinically Diagnosed and/or PCR-confirmed).","description":"The outcome measure is based on the area under the curve (AUC) for the TSS (Total symptoms score).\n\nTSS is calculated as a sum of scores for 14 different symptoms. 13 of them are different ARVI manifestations, each of them is evaluated on a scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe). 14th symptom is body temperature (temp) which is converted to its score using following rules:\n\nif temp \\<= 37.3 then score = 0 (none) if 37.3 \\< temp \\<= 38.0 then score = 1 (mild) if 38.0 \\< temp \\<= 39.0 then score = 2 (moderate) if 39.0 \\< temp then score = 3 (severe) So it is 14 symptoms and the score for each of them varies between 0 and 3. Minimum TSS is 0, maximum is 42 (higher TSS score is worse). AUC is calculated for all timepoints available for patient.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.6","spread":"23.8"},{"groupId":"OG001","value":"46.9","spread":"24.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":"25.2"},{"groupId":"OG001","value":"53.6","spread":"25.6"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).","description":"ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from \"0\" to \"42\". The TSS higher score is the worse outcome.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"136","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"181","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Resolution of ARVI Symptoms (Clinically Diagnosed and/or PCR-confirmed).","description":"ARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from \"0\" to \"42\". The TSS higher score is the worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"1.8"},{"groupId":"OG001","value":"3.9","spread":"2.4"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Resolution of ARVI Symptoms (PCR-confirmed).","description":"Outcome Measure is based on the Percentage of Patients With Resolution of ARVI, confirmed by Polymerase chain reaction (PCR), i.e virus detection.\n\nARVI's resolution criteria: temperature ≤37.3°С + total symptom score (TSS) ≤2. Axillar temperature, 6 flu-like nonspecific symptoms (headache, chills, sweating, weakness, muscle pain, drowsiness) and 7 nasal/throat/chest symptoms (runny nose, nasal congestion, sneezing, hoarseness, sore throat, cough, pain/heaviness in chest) were registered for TSS according to the 4-point scale for each of them (0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom). To calculate TSS absolute axillar temperature (in degrees Celsius) was converted to relative units (or points) using the following scale: ≤37.3 С=0 points; 37.4-38.0 С=1 point; 38.1-39.0 С=2 points; ≥39.1 С=3 points. So the range of TSS was from \"0\" to \"42\". The TSS higher score is the worse outcome.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Dosing Frequency of Antipyretics.","description":"Outcome Measure is based on the rates of antipyretic use per patient during days 1 to 3 of therapy according to the electronic patient diary.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.72"},{"groupId":"OG001","value":"0.39","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.61"},{"groupId":"OG001","value":"0.25","spread":"0.66"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.38"},{"groupId":"OG001","value":"0.07","spread":"0.31"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients Reporting Worsening of Illness.","description":"Outcome Measure is based on the rates of Complications that require the use of antibiotics or hospitalization.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Occurrence and Type of Adverse Events (AE) During the Treatment. AE Severity.","description":"1. The intensity (severity) of adverse events.\n2. Causal relationship of AEs to the sudy drug.\n3. Outcome of AEs. Based on medical records.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Pulse Rate/Heart Rate in Beats Per Minute (Bpm).","description":"The outcome measure is based on the medical records. The patient's heart rate (heart rate) is measured by the physician in every visit (on days 1, 5, and 7).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.1","spread":"11.4"},{"groupId":"OG001","value":"87.2","spread":"10.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.9","spread":"7.1"},{"groupId":"OG001","value":"78.1","spread":"7.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.3","spread":"7.0"},{"groupId":"OG001","value":"76.7","spread":"6.8"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Respiration Rate/Breathing Rate in Breaths Per Minute.","description":"Outcome Measure is based on the medical records. The patient's respiration rate (breathing rate) is measured by physician in every visit (on days 1, 5, and 7).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":"3.3"},{"groupId":"OG001","value":"20.7","spread":"2.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4","spread":"1.9"},{"groupId":"OG001","value":"18.6","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"1.7"},{"groupId":"OG001","value":"18.2","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Changes in Vital Signs: Blood Pressure in Units of Millimeters of Mercury (mmHg).","description":"Outcome Measure is based on the medical records. The patient's blood pressure is measured by the physician in every visit (on days 1, 5, and 7).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"112","spread":"9.9"},{"groupId":"OG001","value":"112","spread":"8.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":"9.8"},{"groupId":"OG001","value":"112","spread":"8.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":"10.2"},{"groupId":"OG001","value":"111","spread":"9.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70.0","spread":"5.7"},{"groupId":"OG001","value":"69.8","spread":"5.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":"5.7"},{"groupId":"OG001","value":"69.5","spread":"5.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":"5.7"},{"groupId":"OG001","value":"69.4","spread":"5.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Clinically Relevant Abnormal Laboratory Findings.","description":"Outcome Measure is based on the Hematology, blood chemistry, and urinalysis parameters, which are beyond the reference values at the end of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":206},"commonTop":["Flu","Adenoiditis","Bacterial superinfection","Viral upper respiratory tract infection","Coronavirus infection COVID-19"]}}}